

1 **Cardiometabolic profile of different body composition phenotypes in children**

2 Yi Ying Ong<sup>1</sup>, Jonathan Y. Huang<sup>2</sup>, Navin Michael<sup>2</sup>, Suresh Anand Sadananthan<sup>2</sup>, Wen Lun  
3 Yuan<sup>1</sup>, Ling-Wei Chen<sup>2</sup>, Neerja Karnani<sup>2</sup>, S. Sendhil Velan<sup>2,3</sup>, Marielle V. Fortier<sup>2,4</sup>, Kok  
4 Hian Tan<sup>5,6</sup>, Peter D. Gluckman<sup>2,7</sup>, Fabian Yap<sup>5,8</sup>, Yap-Seng Chong<sup>2,9</sup>, Keith M. Godfrey<sup>10</sup>,  
5 Mary F-F. Chong<sup>2,11</sup>, Shiao-Yng Chan<sup>2,9</sup>, Yung Seng Lee<sup>1,2,12</sup>, Mya-Thway Tint<sup>\*2,9</sup>, & Johan  
6 G. Eriksson<sup>\*2,9,13,14</sup>

7 **\*Co-corresponding authors**

8 <sup>1</sup>Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

9 <sup>2</sup>Singapore Institute for Clinical Science, Agency for Science, Technology, and Research, Singapore, Singapore.

10 <sup>3</sup>Singapore Bioimaging Consortium, Agency for Science Technology and Research, Singapore, Singapore.

11 <sup>4</sup>Department of Diagnostic and Interventional Imaging, KK Women's and Children's Hospital, Singapore, Singapore.

12 <sup>5</sup>Duke-NUS Medical School, Singapore, Singapore.

13 <sup>6</sup>Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore, Singapore.

14 <sup>7</sup>Liggins Institute, University of Auckland, Auckland, New Zealand.

15 <sup>8</sup>Department of Paediatrics, KK Women's and Children's Hospital, Singapore, Singapore.

16 <sup>9</sup>Department of Obstetrics and Gynaecology and Human Potential Translational Research Programme, Yong Loo Lin School  
17 of Medicine, National University of Singapore, Singapore, Singapore.

18 <sup>10</sup>MRC Lifecourse Epidemiology Unit and NIHR Southampton Biomedical Research Centre, University of Southampton and  
19 University Hospital Southampton NHS Foundation Trust, Southampton, UK.

20 <sup>11</sup>Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

21 <sup>12</sup>Division of Paediatric Endocrinology, Department of Paediatrics, Khoo Teck Puat-National University Children's Medical  
22 Institute, National University Hospital, National University Health System, Singapore.

23 <sup>13</sup>Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital,  
24 Helsinki, Finland.

25 <sup>14</sup>Folkhälsan Research Center, Helsinki, Finland.

26

27 **Keywords:** Body composition, lean, adiposity, cardiometabolic, metabolic syndrome

28

29

30

31 **Corresponding authors:**

32 **Johan G. Eriksson**

33 Department of Obstetrics and Gynaecology and Human Potential Research Programme,  
34 Yong Loo Lin School of Medicine, National University of Singapore MD1, Tahir Foundation  
35 Building, Level 12, #12-02/03, 12 Science Drive 2, Singapore 117549, Email:  
36 [objge@nus.edu.sg](mailto:objge@nus.edu.sg), Tel: 65-6516 4079, Fax: 65-6779 4753

37

38 **Mya-Thway Tint**

39 Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research  
40 (A\*STAR), Brenner Centre for Molecular Medicine, 30 Medical Drive, Singapore 117609,  
41 Email: [Mya\\_Thway\\_Tint@sics.a-star.edu.sg](mailto:Mya_Thway_Tint@sics.a-star.edu.sg), Tel: 65-66011947

42

43 **Funding/Support:** This work was supported by the Singapore National Research Foundation  
44 under its Translational and Clinical Research (TCR) Flagship Programme and administered  
45 by the Singapore Ministry of Health's National Medical Research Council (NMRC),  
46 Singapore [NMRC/TCR/004-NUS/2008, NMRC/TCR/012-NUHS/2014]. Additional funding  
47 is provided by the Singapore Institute for Clinical Sciences, Agency for Science Technology  
48 and Research, Singapore.

49

50 **Disclosure Statement:** YSC, KMG, and SYC are part of an academic consortium that has  
51 received research funding from companies selling nutritional products. KMG and SYC has  
52 received reimbursement for speaking at conferences sponsored by companies selling  
53 nutritional products. KMG is supported by the UK Medical Research Council  
54 (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator  
55 (NF-SI-0515-10042), NIHR Southampton 1000DaysPlus Global Nutrition Research Group

## Body composition and child cardiometabolic profile

56 (17/63/154) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)),  
57 the European Union (Erasmus+ Programme Early Nutrition eAcademy Southeast Asia-  
58 573651-EPP-1-2016-1-DE-EPPKA2-CBHE-JP and ImpENSA 598488-EPP-1-2018-1-DE-  
59 EPPKA2-CBHE-JP) and the British Heart Foundation (RG/15/17/3174). All other authors  
60 have nothing to disclose.

61

62

63

64

65 **Abstract**

66 **Context**

67 Cardiometabolic profiles of different body composition phenotypes are poorly characterized in  
68 young children, where it is well-established that high adiposity is unfavorable, but the role of  
69 lean mass is unclear.

70 **Objective**

71 We hypothesized that higher lean mass attenuates cardiometabolic risk in children with high  
72 fat mass.

73 **Design, Setting, Participants**

74 In 6-year-old children (n=377) from the Growing Up in Singapore Towards healthy Outcomes  
75 (GUSTO) prospective birth cohort, whole-body composition was measured by quantitative  
76 magnetic resonance, a novel validated technology. Based on fat mass index (FMI) and lean  
77 mass index (LMI), 4 body composition phenotypes were derived: low FMI-low LMI (LF-LL),  
78 low FMI-high LMI (LF-HL), high FMI-low LMI (HF-LL), high FMI-high LMI (HF-HL).

79 **Main Outcome Measures**

80 BMI z-score, fasting plasma glucose, insulin resistance, metabolic syndrome risk score, fatty  
81 liver index, and blood pressure

82 **Results**

83 Compared to the LF-HL group, children in both high FMI groups had increased BMI z-score  
84 (HF-HL: 1.43units 95% CI [1.11,1.76]; HF-LL: 0.61units [0.25,0.96]) and metabolic syndrome  
85 risk score (HF-HL: 1.64 [0.77,2.50]; HF-LL: 1.28 [0.34,2.21]). The HF-HL group also had  
86 increased fatty liver index (1.15 [0.54,1.77]). Girls in HF-HL group had lower fasting plasma

87 glucose (-0.29mmol/L [-0.55,-0.04]) and diastolic blood pressure (-3.22mmHg [-6.03,-0.41])  
88 than girls in the HF-LL group. No similar associations were observed in boys.

89 **Conclusions**

90 In a multi-ethnic Asian cohort, lean mass seemed to protect against some cardiometabolic risk  
91 markers linked with adiposity, but only in girls. Fat mass index seemed more important than  
92 lean mass index in relation to cardiometabolic profiles of young children.

93

94 **Introduction**

95 An adverse cardiometabolic risk profile and adiposity in childhood are becoming  
96 increasingly prevalent and are linked to poorer cardiometabolic health later in life(1,2).  
97 Traditionally, BMI cut-offs of “overweight” and “obesity” have been used to identify high-risk  
98 children. However, BMI might not be a good indicator of adiposity as it does not distinguish  
99 between fat, muscle, or bone. Further, BMI depends on factors including age, sex, ethnicity,  
100 and maturation stage(3,4). Disentangling the fat and lean components of total body mass and  
101 studying different body composition phenotypes might provide additional insights on  
102 childhood cardiometabolic risk due to the differing roles of lean and fat mass in health and  
103 disease.

104 Whole-body lean mass includes skeletal muscle, which is the largest insulin-sensitive  
105 tissue in the body responsible for insulin-mediated glucose disposal(5). A progressive loss of  
106 skeletal muscle with aging(6), known as sarcopenia, is linked to the metabolic syndrome(7,8).  
107 However, the role of skeletal muscle or lean mass on child cardiometabolic profile is unclear.  
108 Lean mass has been reported to be relatively protective of vascular structure and function in  
109 children(9) and lower appendicular skeletal muscle mass relative to total body fat is linked to  
110 metabolic syndrome risk in overweight children(10). In contrast, increased lean mass index  
111 (LMI) has also been linked to decreased high-density lipoprotein and increased  
112 cardiometabolic risk factors, independent of fat mass index (FMI), in children and  
113 adolescents(11,12). Compared to lean mass, the role of fat mass is more well-established.  
114 Higher FMI, calculated using fat mass divided by height squared, is linked to adverse  
115 cardiometabolic profiles in adults and children(9,12–17). However, it is unknown if lean mass  
116 attenuates the adverse effect of fat mass on cardiometabolic health, especially in young children  
117 where the role of lean mass is unclear.

118 As adverse cardiometabolic profiles tend to track from early childhood to  
119 adulthood(1,2), early risk stratification is important. However, the cardiometabolic profile of  
120 different body composition phenotypes are not well characterized in young children. Previous  
121 studies usually involved older children aged 8 to 19 years(9–12), probably due to measurement  
122 of body composition by dual X-ray absorptiometry, where radiation exposure might be a  
123 concern(18,19).

124 We aimed to characterize the cardiometabolic profile of distinct body composition  
125 phenotypes in young children aged 6 years by measuring whole-body lean and fat mass using  
126 a novel, validated quantitative nuclear magnetic resonance technology(20). We hypothesized  
127 that high fat mass is associated with adverse cardiometabolic profiles while high lean mass  
128 may attenuate the adverse cardiometabolic profile in children with high fat mass. Sex-specific  
129 interactions will also be investigated as sex differences in body composition and  
130 cardiometabolic markers can be observed even before puberty(21).

131

## 132 **Materials and methods**

### 133 *Study population*

134 Children were from the Growing Up in Singapore Towards healthy Outcomes  
135 (GUSTO) prospective birth cohort study recruited from two major public hospitals in  
136 Singapore – the KK Women's and Children's Hospital and the National University Hospital –  
137 between 2009 and 2010(22). Pregnant women in their first trimester were eligible if they were  
138 Singapore citizens or permanent residents aged 18 years and above, planned to deliver in KK  
139 Women's and Children's Hospital or National University Hospital, live in Singapore for the  
140 next 5 years, willing to donate birth tissues at delivery, not receiving chemotherapy, not on  
141 psychotropic drugs, and not having type 1 diabetes. At a clinical follow-up visit at 6 years of  
142 age out of 1026 children approached for body composition analysis, 377 children were included

143 (Figure 1). The main reasons for not being included were no access to the body composition  
144 machine (n=255), parental concerns (n=372) and other reasons (n=22) including machine  
145 related issues. Ethic approvals were granted from the National Healthcare Group Domain  
146 Specific Review Board and SingHealth Centralized Institutional Review Board. The children  
147 filled an assent form to document their understanding and participation in the study while their  
148 parents gave written informed consent.

149 *Body composition*

150 Whole-body lean mass and fat mass were measured by EchoMRI™ Adolescent  
151 Humans Body Composition Analyzer (EchoMRI Corporation, Singapore)(20). EchoMRI™  
152 uses quantitative nuclear magnetic resonance technology based on stimulation of hydrogen  
153 nuclei in a magnetic field by radio frequency pulses. Relaxation of the hydrogen nuclei  
154 generates radio signals that are different in fat and lean mass, enabling differentiation of these  
155 tissues. Therefore, lean mass measured by EchoMRI™ excludes fat, bone minerals, and  
156 substances which do not contribute to the nuclear magnetic resonance signal, such as hair and  
157 nails. Quality control measures for EchoMRI™ were performed daily according to the  
158 manufacturer's recommendations, including calibration of the machine with 8 bottles of canola  
159 oil. Children were measured in light clothing, in the supine position, and instructed to minimize  
160 their movement, although slight motions are generally well-tolerated. FMI and LMI were  
161 calculated using fat mass or lean mass (kg) divided by height (m) squared and dichotomized  
162 into "high" and "low" groups based on cohort- and sex-specific medians to derive four distinct  
163 body composition groups: low FMI-low LMI (LF-LL), low FMI-high LMI (LF-HL), high  
164 FMI-low LMI (HF-LL) and high FMI-high LMI (HF-HL).

165

166 *Cardiometabolic markers at age 6 years*



167 Cardiometabolic markers were measured in subsets of children who attended the study  
168 visit and gave consent for the various measures, described below.

169 Standing height (SECA213 stadiometer), weight (SECA803 Weighing Scale) and  
170 abdominal circumference (measuring tape) were measured using standardized protocols(22).  
171 Sex and age standardized z-scores of BMI (z-BMI) and height (z-height) were calculated using  
172 World Health Organization growth standards(23).

173 After an overnight fast, venous blood was drawn to measure fasting plasma glucose  
174 (Abbott Architect c8000 analyzer at KK Women's and Children's Hospital and Beckman  
175 AU5800 analyzer at National University Hospital) as well as serum insulin (Beckman DXL800  
176 analyzer, Beckman Coulter), high density lipoprotein cholesterol (Beckman AU5800 analyzer,  
177 Beckman Coulter), triglycerides, and gamma-glutamyl-transferase (Beckman AU5800  
178 analyzer, Beckman Coulter). Homeostasis model assessment of insulin resistance was  
179 calculated using the following formula(24): [fasting insulin (mU/L) \* fasting glucose (mmol/L)]  
180 / 22.5.

181 Peripheral systolic blood pressure and diastolic blood pressure were measured  
182 (Dinamap CARESCAPE V100, GE Healthcare, Milwaukee, WI) from the right upper arm by  
183 trained research coordinators using a standardized protocol(25).

184 A pediatric metabolic syndrome risk score was calculated based on a previously  
185 published equation(26). First, cohort-specific sex-standardized abdominal circumference,  
186 systolic blood pressure, diastolic blood pressure, homeostasis model assessment of insulin  
187 resistance, triglycerides, and high density lipoprotein cholesterol z-scores were derived. Then,  
188 metabolic syndrome risk score was calculated by summing the z-scores of four components of  
189 cardiometabolic risk: 1) abdominal circumference, 2) mean z-scores of systolic and diastolic  
190 blood pressure, 3) homeostasis model assessment of insulin resistance and 4) mean z-scores of  
191 triglycerides and high density lipoprotein cholesterol (z-score of high density lipoprotein

192 cholesterol multiplied with  $-1$ , due to its inverse association with metabolic risk). Fatty liver  
193 index was calculated based on a published equation using triglycerides, gamma-glutamyl-  
194 transferase, and abdominal circumference(27). It is an index to estimate non-alcoholic fatty  
195 liver disease with modest efficacy compared to magnetic resonance spectroscopy which is  
196 expensive and not routinely accessible.

197

### 198 *Covariates*

199 Ethnicity, age, household income, and self-reported pre-pregnancy weight were  
200 obtained through interviewer-administered questionnaires. A 75g 2h-oral glucose tolerance test  
201 was performed to measure gestational (26-28 weeks) fasting plasma glucose and 2-hour plasma  
202 glucose [Advia 2400 Chemistry system (Siemens Medical Solutions Diagnostics, Deerfield,  
203 IL, USA) and Beckman LX20 Pro analyser (Beckman Coulter, USA)]. Gestational diabetes  
204 was diagnosed according to the 1999 World Health Organization criteria (fasting plasma  
205 glucose  $\geq 7.0$ mmol/L or 2-hour plasma glucose  $\geq 7.8$ mmol/l). Infant's birthweight and sex were  
206 obtained from medical records. Gestational age was derived based on first trimester ultrasound  
207 scans. Cohort-specific birthweight percentiles, adjusted for sex and gestational age, were  
208 calculated(28) to identify small-for-gestational-age (birthweight  $< 10^{\text{th}}$  centile), large-for-  
209 gestational-age (birthweight  $> 90^{\text{th}}$  centile), and appropriate-for-gestational-age infants(28).

210

### 211 *Statistical analyses*

212 We analyzed differences in baseline sociodemographic and clinical characteristics  
213 between the body composition groups using one-way ANOVA for continuous variables and  
214 chi-square test for categorical variables. Multiple linear regression was performed to analyze  
215 associations between the body composition groups and cardiometabolic markers at age 6 years,  
216 adjusted for ethnicity, sex, household income, maternal age, pre-pregnancy body mass index,

217 gestational diabetes, prematurity, and size at birth, to reduce confounding bias by these  
218 potential confounders.

219 Differences in cardiometabolic markers for the body composition groups of primary  
220 interest, HF-HL and HF-LL, together with LF-LL, were compared against the LF-HL group,  
221 which was used as the reference group because it was hypothesized to be the healthy group  
222 among the four body composition groups. Differences in cardiometabolic markers between the  
223 two body composition groups with high FMI (HF-HL vs. HF-LL) were compared to determine  
224 whether the HF-HL group was metabolically favorable compared to HF-LL. By including a  
225 multiplicative interaction term, significant interactions were found between sex and body  
226 composition groups with high FMI (HF-HL, HF-LL) on two outcomes: fasting plasma glucose  
227 and diastolic blood pressure. Sex-stratified analyses were presented for these outcomes. All  
228 analyses were performed using the Stata16.0 software (StataCorp LP, TX). Two-sided P values  
229 <0.05 were considered statistically significant.

230

## 231 **Results**

### 232 *Population characteristics*

233 Table 1 shows the characteristics of the 377 children who participated in this study  
234 grouped by body composition groups: LF-HL (21%), LF-LL (29%), HF-HL (29%), HF-LL  
235 (21%). There were 202 (53.6%) Chinese, 113 (30.0%) Malay, and 62 (16.4%) Indian children.

236 Children in the 4 body composition phenotype groups had differing sociodemographic  
237 characteristics. Compared to all children included in this study, the LF-HL group had a higher  
238 proportion of children of Chinese ethnicity and who came from high income households. The  
239 HF-HL group included a higher proportion of children of Malay ethnicity and who came from  
240 low income households, while the HF-LL group included a higher proportion of children of

241 Indian ethnicity and who had older mothers (Table 1). Children in the 4 body composition  
242 phenotype groups also had differing maternal prenatal and perinatal characteristics. Children  
243 in the LF-LL group had mothers with the lowest mean pre-pregnancy BMI, gestational fasting  
244 plasma glucose, and had the highest prevalence of preterm and small-for-gestational-age  
245 infants. In contrast, children in the HF-HL group had mothers with the highest mean pre-  
246 pregnancy BMI, gestational fasting plasma glucose, and had the highest prevalence of large-  
247 for-gestational-age infants. Mothers of children in the HF-LL group had the highest prevalence  
248 of gestational diabetes.

249

#### 250 *Cardiometabolic profile of body composition phenotypes*

251 Adjusting for confounders, both high FMI groups (HF-HL and HF-LL) had several  
252 elevated cardiometabolic markers compared to the LF-HL reference group. Higher z-BMI was  
253 observed in the HF-HL group,  $\beta$  (95% CI), 1.43units (1.11, 1.76) and HF-LL group, 0.61units  
254 (0.25, 0.96) (Table 2). Higher metabolic syndrome risk score was also observed in the HF-HL  
255 group, 1.64 (0.77, 2.50) and HF-LL group, 1.28 (0.34, 2.21). In addition, the HF-HL group had  
256 higher fatty liver index, 1.15 (0.54, 1.77). Comparing the low FMI groups (LF-LL vs. LF-HL),  
257 other than having lower z-BMI, -0.72units (-1.05, -0.40) the LF-LL group did not differ  
258 significantly in any other cardiometabolic risk markers compared to the LF-HL reference  
259 group.

260

#### 261 *Lean mass in children with high adiposity*

262 Comparing the high FMI body composition groups which were of interest (HF-HL vs.  
263 HF-LL), other than having higher z-BMI, 0.89units (0.45,1.32), the HF-HL group did not differ  
264 significantly in any other cardiometabolic risk markers compared to the HF-LL group (Table  
265 3). There were significant interactions between sex and the two body composition groups (HF-

266 HL and HF-LL) on fasting plasma glucose and diastolic blood pressure,  $P=0.006$  and  $0.03$ ,  
267 respectively (Table 4). Compared to the HF-LL group, girls from the HF-HL group had lower  
268 fasting plasma glucose,  $-0.29$  mmol/L ( $-0.55$ ,  $-0.04$ ) and lower diastolic blood pressure, -  
269  $3.22$ mmHg ( $-6.03$ ,  $-0.41$ ). These associations were not significant in boys.

270

## 271 **Discussion**

272 In the present study, 6-year-old children in the “high FMI” body composition phenotype  
273 groups had more adverse cardiometabolic profiles compared with those with low FMI. Among  
274 children with high FMI, having high LMI seems to slightly attenuate the adverse  
275 cardiometabolic profile, but only in girls. The potentially sex-specific protective role of lean  
276 mass on cardiometabolic profile of girls with high adiposity needs to be confirmed in larger  
277 studies and other populations. In contrast, among children with low FMI, high LMI was not  
278 linked to significantly different cardiometabolic profiles, suggesting that the potentially  
279 protective effect of LMI might not be detectable in children with low adiposity. Our study  
280 suggests that in young children, the protective role of high LMI is neither strong nor consistent.  
281 Therefore, it might be important to focus on all children with high FMI for early risk  
282 stratification, monitoring, and potential interventions.

283 Consistent with the literature on older children and adults, we observed strong  
284 associations between high FMI groups and adverse cardiometabolic risk markers in young  
285 children. By estimating fat mass and fat-free mass based on a combination of bioelectrical  
286 impedance and body measurements, a longitudinal study which followed up children aged 8,  
287 11, and 14 years for up to 4 years found that the association between BMI and adverse blood  
288 lipid levels was mainly attributable to FMI, rather than the fat-free mass index(29). Pooled  
289 analysis of two adult twin cohorts, which measured body composition by dual X-ray

290 absorptiometry and bioelectrical impedance, respectively, similarly found that FMI was more  
291 strongly associated with cardiometabolic profile than fat-free mass index(30). We also  
292 observed that children from the high FMI groups were more likely to be from minority  
293 ethnicities, from low income households, and to have mothers with higher pre-pregnancy BMI  
294 and gestational glycemia. Hence, FMI seems to be a good marker of cardiometabolic risk in  
295 young children and curbing excessive child adiposity through diet(31,32) or exercise(33),  
296 especially focusing on families with socioeconomic disadvantage or mothers with prenatal risk  
297 factors, might be vital for optimizing cardiometabolic health.

298         Several studies in children, adolescents, and adults have reported associations between  
299 increased lean mass, skeletal muscle mass, or muscle to fat ratio, with more favorable  
300 cardiometabolic profiles. In Korean children and adolescents aged 10–18 years, increased  
301 appendicular skeletal muscle to body fat ratio was associated with lower cardiometabolic  
302 risk(10) while in Chilean adolescents aged 16 to 17 years, low lean mass was associated with  
303 higher cardiometabolic risk(34). In 17 280 Korean adults (mean age: 48.1±8.2 years),  
304 transitioning from a low fat-high muscle phenotype to any of the low muscle phenotypes over  
305 the 5 year follow-up period was associated with increased type 2 diabetes risk(35). Hence, we  
306 hypothesized that increased lean mass might attenuate adverse cardiometabolic profiles in  
307 children with high adiposity.

308         Our findings suggest potential sex-specific protective effects of high LMI on  
309 cardiometabolic markers in girls with high FMI. Among girls with high FMI, high LMI was  
310 associated with slight reductions in fasting plasma glucose and diastolic blood pressure,  
311 without significant changes in any other cardiometabolic risk markers investigated. Sex-  
312 specific associations between body composition and cardiometabolic risk have been reported  
313 in other studies(10). One explanation might be that the protective effects of LMI are greater  
314 and more easily detected in people at higher cardiometabolic risk, such as older adults(35), or

315 children with higher adiposity(10) such as girls in our cohort who had higher mean FMI than  
316 boys. Another explanation is there might be sex-specific differences in body fat partitioning  
317 where boys in our cohort might concurrently have high lean mass and high intramyocellular  
318 lipids, which is associated with skeletal muscle insulin resistance and attenuates the protective  
319 effect of lean mass(36). However, our imaging technique using quantitative magnetic  
320 resonance measures total body fat and will therefore not provide information on specific body  
321 fat partitioning such as intramyocellular fat.

322 Overall, in young children, the protective effect of LMI seems to be weak and sex-  
323 specific. In pooled analyses, we found that children in the HF-HL group had similarly elevated  
324 cardiometabolic risk markers as children in the HF-LL group, consistent with a cross-sectional  
325 study in 14 807 Korean adults aged 18-65 years, which suggests no significant protective role  
326 of lean mass among people with high adiposity(37). A few studies even reported detrimental,  
327 instead of protective, effects of LMI or fat-free mass index on cardiometabolic risk. In adults  
328 aged 50–70 years, higher fat-free mass index was independently associated with metabolic  
329 syndrome risk after adjusting for fat mass(13) while in adolescents aged 12-20 years, LMI was  
330 positively associated with elevated cardiometabolic risk markers, even after adjustment for  
331 FMI(11). The biological mechanisms for the contrasting associations between lean mass and  
332 cardiometabolic markers are poorly understood and further studies are required.

333 This study has several strengths and limitations. First, it involves the use of a novel,  
334 validated quantitative nuclear magnetic resonance technology (EchoMRI<sup>TM</sup>), with several  
335 advantages over other methods of measuring body composition such as bioelectrical impedance  
336 analysis, air displacement plethysmography, or dual X-ray absorptiometry. Unlike bioelectrical  
337 impedance analysis and air displacement plethysmography, EchoMRI<sup>TM</sup> is more tolerant to  
338 movement, not influenced by body hydration, and not based on assumptions from derived body  
339 density models or density of fat-free mass(20). Unlike dual X-ray absorptiometry, EchoMRI<sup>TM</sup>

340 does not involve radiation and is suitable for use in young children. Second, in our deeply-  
341 phenotyped cohort, we measured a comprehensive panel of cardiometabolic risk markers,  
342 which included blood glucose and lipids, a holistic pediatric metabolic syndrome score, and  
343 fatty liver index, to capture any early subclinical changes in cardiometabolic profile. Third, we  
344 prospectively collected a range of socio-demographic factors, maternal comorbidities, and  
345 perinatal factors which reduced recall bias and enabled us to further understand the associations  
346 independent of these potential confounders. Limitations of our study include the cross-sectional  
347 design which prevents us from making causal inferences of the effects of different FMI and  
348 LMI composition on cardiometabolic markers. The sample size for each body composition  
349 group is relatively small, especially for sex-specific analyses. We did not investigate tissue-  
350 specific distribution of fats such as intramyocellular lipids and liver fat, which might also  
351 contribute to the observed cardiometabolic profile(38). Caution must be taken when trying to  
352 generalize findings from our multi-ethnic Asian cohort to other populations.

353

## 354 **Conclusions**

355 From the four body composition phenotypes characterized, young children with high  
356 FMI had elevated cardiometabolic risk markers, regardless of level of LMI. Hence, preventing  
357 excessive accumulation of fat rather than optimizing lean mass might be vital to curb the early  
358 development of cardiometabolic risk. Further studies are needed to confirm the potentially sex-  
359 specific protective role of LMI in children with high FMI, and to understand the evolving role  
360 of lean mass over the life course.

361



362 **Acknowledgements**

363 We thank all GUSTO participants as well as the GUSTO study group, which includes Allan  
364 Sheppard, Amutha Chinnadurai, Anne Eng Neo Goh, Anne Rifkin-Graboi, Anqi Qiu, Arijit  
365 Biswas, Bee Wah Lee, Birit F.P. Broekman, Boon Long Quah, Borys Shuter, Chai Kiat Chng,  
366 Cheryl Ngo, Choon Looi Bong, Christiani Jeyakumar Henry, Claudia Chi, Cornelia Yin Ing  
367 Chee, Yam Thiam Daniel Goh, Doris Fok, E Shyong Tai, Elaine Tham, Elaine Quah Phaik  
368 Ling, Evelyn Chung Ning Law, Evelyn Xiu Ling Loo, Falk Mueller-Riemenschneider, George  
369 Seow Heong Yeo, Helen Chen, Heng Hao Tan, Hugo P S van Bever, Iliana Magiati, Inez Bik  
370 Yun Wong, Ivy Yee-Man Lau, Izzuddin Bin Mohd Aris, Jeevesh Kapur, Jenny L. Richmond,  
371 Jerry Kok Yen Chan, Joanna D. Holbrook, Joanne Yoong, Joao N. Ferreira., Jonathan Tze  
372 Liang Choo, Jonathan Y. Bernard, Joshua J. Gooley, Kenneth Kwek, Krishnamoorthy  
373 Niduvaje, Kuan Jin Lee, Leher Singh, Lieng Hsi Ling, Lin Lin Su, Lourdes Mary Daniel,  
374 Lynette P Shek, Mark Hanson, Mary Rauff, Mei Chien Chua, Melvin Khee-Shing Leow,  
375 Michael Meaney, Ngee Lek, Oon Hoe Teoh, P. C. Wong, Paulin Tay Straughan, Pratibha  
376 Agarwal, Queenie Ling Jun Li, Rob M. van Dam, Salome A. Rebello, Seang-Mei Saw, See  
377 Ling Loy, Seng Bin Ang, Shang Chee Chong, Sharon Ng, Shirong Cai, Shu-E Soh, Sok Bee  
378 Lim, Stella Tsotsi, Chin-Ying Stephen Hsu, Sue Anne Toh, Swee Chye Quek, Victor Samuel  
379 Rajadurai, Walter Stunkel, Wayne Cutfield, Wee Meng Han, Wei Wei Pang, Yin Bun Cheung,  
380 and Yiong Huak Chan

381

382 **Data availability statement: Restrictions apply to the availability of some or all data**  
383 **generated or analyzed during this study to preserve patient confidentiality or because**  
384 **they were used under license. The corresponding author will on request detail the**  
385 **restrictions and any conditions under which access to some data may be provided.**



## References

1. **Camhi SM, Katzmarzyk PT.** Tracking of cardiometabolic risk factor clustering from childhood to adulthood. *International Journal of Pediatric Obesity* 2010;5(2):122–129.
2. **Salbe AD, Weyer C, Lindsay RS, Ravussin E, Tataranni PA.** Assessing Risk Factors for Obesity Between Childhood and Adolescence: I. Birth Weight, Childhood Adiposity, Parental Obesity, Insulin, and Leptin. *Pediatrics* 2002;110(2):299–306.
3. **Daniels SR, Khoury PR, Morrison JA.** The Utility of Body Mass Index as a Measure of Body Fatness in Children and Adolescents: Differences by Race and Gender. *Pediatrics* 1997;99(6):804–807.
4. **Demerath EW, Schubert CM, Maynard LM, Sun SS, Chumlea WC, Pickoff A, Czerwinski SA, Towne B, Siervogel RM.** Do Changes in Body Mass Index Percentile Reflect Changes in Body Composition in Children? Data From the Fels Longitudinal Study. *Pediatrics* 2006;117(3):e487–e495.
5. **Stump CS, Henriksen EJ, Wei Y, Sowers JR.** The metabolic syndrome: role of skeletal muscle metabolism. *Ann. Med.* 2006;38(6):389–402.
6. **Rosenberg IH.** Sarcopenia: origins and clinical relevance. *J. Nutr.* 1997;127(5 Suppl):990S-991S.
7. **Moon S-S.** Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. *Endocr. J.* 2014;61(1):61–70.
8. **Lee J, Hong Y, Shin HJ, Lee W.** Associations of Sarcopenia and Sarcopenic Obesity With Metabolic Syndrome Considering Both Muscle Mass and Muscle Strength. *J Prev Med Public Health* 2016;49(1):35–44.
9. **Sletner L, Mahon P, Crozier SR, Inskip HM, Godfrey KM, Chiesa S, Bhowruth DJ, Charakida M, Deanfield J, Cooper C, Hanson M.** Childhood fat and lean mass: differing relations to vascular structure and function at age 8-9-years. *Arterioscler Thromb Vasc Biol* 2018;38(10):2528–2537.
10. **Kim K, Hong S, Kim EY.** Reference Values of Skeletal Muscle Mass for Korean Children and Adolescents Using Data from the Korean National Health and Nutrition Examination Survey 2009-2011. *PLoS One* 2016;11(4). doi:10.1371/journal.pone.0153383.
11. **Weber DR, Leonard MB, Shults J, Zemel BS.** A Comparison of Fat and Lean Body Mass Index to BMI for the Identification of Metabolic Syndrome in Children and Adolescents. *J Clin Endocrinol Metab* 2014;99(9):3208–3216.
12. **Duran I, Martakis K, Schafmeyer L, Jackels M, Rehberg M, Schoenau E.** Inverse Association of High-Density Lipoprotein Cholesterol Concentration with Muscle Mass in Children. *Childhood Obesity* 2019;15(7):476–484.

13. **Wang J, Rennie KL, Gu W, Li H, Yu Z, Lin X.** Independent associations of body-size adjusted fat mass and fat-free mass with the metabolic syndrome in Chinese. *Annals of Human Biology* 2009;36(1):110–121.
14. **Ramírez-Vélez R, Correa-Bautista JE, Sanders-Tordecilla A, Ojeda-Pardo ML, Cobo-Mejía EA, Castellanos-Vega RDP, García-Hermoso A, González-Jiménez E, Schmidt-RioValle J, González-Ruiz K.** Percentage of Body Fat and Fat Mass Index as a Screening Tool for Metabolic Syndrome Prediction in Colombian University Students. *Nutrients* 2017;9(9):1009.
15. **Liu P, Ma F, Lou H, Liu Y.** The utility of fat mass index vs. body mass index and percentage of body fat in the screening of metabolic syndrome. *BMC Public Health* 2013;13(1):629.
16. **Kim JY, Oh S, Chang MR, Cho YG, Park KH, Paek YJ, Yoo SH, Cho JJ, Caterson ID, Song HJ.** Comparability and utility of body composition measurement vs. anthropometric measurement for assessing obesity related health risks in Korean men. *International Journal of Clinical Practice* 2013;67(1):73–80.
17. **Pasdar Y, Hamzeh B, Najafi F, Darbandi M.** Optimal cutoff values of fat mass index, body fat percentage and visceral fat area for identifying metabolic syndrome in the Kurdish population: Results from an Iranian RaNCD cohort study. *Mediterranean Journal of Nutrition and Metabolism* 2019;12(4):397–409.
18. **Baur LA.** Body composition measurement in normal children: ethical and methodological limitations. *Asia Pacific Journal of Clinical Nutrition* 1995;4(1):35–38.
19. **Wasserman H, O'Donnell JM, Gordon CM.** Use of dual energy X-ray absorptiometry in pediatric patients. *Bone* 2017;104:84–90.
20. **Chen L-W, Tint M-T, Fortier MV, Aris IM, Shek LP-C, Tan KH, Rajadurai VS, Gluckman PD, Chong Y-S, Godfrey KM, Kramer MS, Henry CJ, Yap F, Lee YS.** Body composition measurement in young children using quantitative magnetic resonance: a comparison with air displacement plethysmography. *Pediatr Obes* 2018;13(6):365–373.
21. **Ayyavoo A, Derraik JGB, Hofman PL, Biggs J, Cutfield WS.** Metabolic, cardiovascular and anthropometric differences between prepubertal girls and boys. *Clin. Endocrinol. (Oxf)* 2014;81(2):238–243.
22. **Soh S-E, Tint MT, Gluckman PD, Godfrey KM, Rifkin-Graboi A, Chan YH, Stükel W, Holbrook JD, Kwek K, Chong Y-S, Saw SM.** Cohort Profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. *Int J Epidemiol* 2014;43(5):1401–1409.
23. **WHO Multicentre Growth Reference Study Group.** WHO child growth standards: length/height for age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age, methods and development. *Geneva: World Health Organization* 2006. Available at: [http://www.who.int/childgrowth/standards/technical\\_report/en/](http://www.who.int/childgrowth/standards/technical_report/en/). Accessed November 19, 2018.

24. **Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.** Homeostasis model assessment: insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28(7):412–419.
25. **Aris IM, Bernard JY, Chen L-W, Tint MT, Lim WY, Soh SE, Saw S-M, Shek LP-C, Godfrey KM, Gluckman PD, Chong Y-S, Yap F, Kramer MS, Lee YS.** Postnatal height and adiposity gain, childhood blood pressure and prehypertension risk in an Asian birth cohort. *International Journal of Obesity* 2017;41(7):1011–1017.
26. **Ahrens W, Moreno LA, Mårild S, Molnár D, Siani A, De Henauw S, Böhm J, Günther K, Hadjigeorgiou C, Iacoviello L, Lissner L, Veidebaum T, Pohlmann H, Pigeot I.** Metabolic syndrome in young children: definitions and results of the IDEFICS study. *International Journal of Obesity* 2014;38(S2):S4–S14.
27. **Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C.** The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006;6:33.
28. **Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gülmezoglu AM, Merialdi M.** A global reference for fetal-weight and birthweight percentiles. *The Lancet* 2011;377(9780):1855–1861.
29. **Dai S, Eissa MA, Steffen LM, Fulton JE, Harrist RB, Labarthe DR.** Associations of BMI and its fat-free and fat components with blood lipids in children: Project HeartBeat! *Clin Lipidol* 2011;6(2):235–244.
30. **Jukarainen S, Holst R, Dalgård C, Piirilä P, Lundbom J, Hakkarainen A, Lundbom N, Rissanen A, Kaprio J, Kyvik KO, Sørensen TIA, Pietiläinen KH.** Cardiorespiratory Fitness and Adiposity as Determinants of Metabolic Health—Pooled Analysis of Two Twin Cohorts. *J Clin Endocrinol Metab* 2017;102(5):1520–1528.
31. **Papadaki A, Linardakis M, Larsen TM, Baak MA van, Lindroos AK, Pfeiffer AFH, Martinez JA, Handjieva-Darlenska T, Kunesová M, Holst C, Astrup A, Saris WHM, Kafatos A.** The Effect of Protein and Glycemic Index on Children’s Body Composition: The DiOGenes Randomized Study. *Pediatrics* 2010;126(5):e1143–e1152.
32. **Gillman MW, Rifas-Shiman SL, Fernandez-Barres S, Kleinman K, Taveras EM, Oken E.** Beverage Intake During Pregnancy and Childhood Adiposity. *Pediatrics* 2017;140(2). doi:10.1542/peds.2017-0031.
33. **Johnson MS, Figueroa-Colon R, Herd SL, Fields DA, Sun M, Hunter GR, Goran MI.** Aerobic Fitness, Not Energy Expenditure, Influences Subsequent Increase in Adiposity in Black and White Children. *Pediatrics* 2000;106(4):e50–e50.
34. **Burrows R, Correa-Burrows P, Reyes M, Blanco E, Albala C, Gahagan S.** Low muscle mass is associated with cardiometabolic risk regardless of nutritional status in adolescents: A cross-sectional study in a Chilean birth cohort. *Pediatric Diabetes* 2017;18(8):895–902.
35. **Kim H-K, Lee MJ, Kim E-H, Bae S-J, Choe J, Kim C-H, Park J-Y.** Longitudinal Changes of Body Composition Phenotypes and Their Association with Incident Type 2

Diabetes Mellitus during a 5-Year Follow-up in Koreans. *Diabetes Metab J* 2019;43(5):627–639.

36. **Brumbaugh DE, Crume TL, Nadeau K, Scherzinger A, Dabelea D.** Intramyocellular Lipid Is Associated with Visceral Adiposity, Markers of Insulin Resistance, and Cardiovascular Risk in Prepubertal Children: The EPOCH Study. *J Clin Endocrinol Metab* 2012;97(7):E1099–E1105.
37. **Kim K, Park SM.** Association of muscle mass and fat mass with insulin resistance and the prevalence of metabolic syndrome in Korean adults: a cross-sectional study. *Scientific Reports* 2018;8(1):2703.
38. **Larson-Meyer DE, Newcomer BR, Ravussin E, Volaufova J, Bennett B, Chalew S, Cefalu WT, Sothorn M.** Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. *Diabetologia* 2011;54(4):869–875.

**Figure legends**

Figure 1: Study flow chart showing children who participated in this study

Body composition and child cardiometabolic profile

Table 1: Characteristics of study participants by body composition groups

	All (n=377), mean (SD) or n (%)	Low FMI- High LMI (n=79), mean (SD) or n (%)	Low FMI- Low LMI (n=109), mean (SD) or n (%)	High FMI- High LMI (n=110), mean (SD) or n (%)	High FMI- Low LMI (n=79), mean (SD) or n (%)	p
<b>Parental characteristics</b>						
Ethnicity						0.009
Chinese	202 (53.6%)	49 (62.0%)	61 (56.0%)	48 (43.6%)	44 (55.7%)	
Malay	113 (30.0%)	25 (31.6%)	29 (26.6%)	43 (39.1%)	16 (20.3%)	
Indian	62 (16.4%)	5 (6.3%)	19 (17.4%)	19 (17.3%)	19 (24.1%)	
Monthly household income						0.03
High (≥ S\$6000)	73 (20.9%)	21 (28.8%)	22 (22.0%)	19 (18.4%)	11 (15.1%)	
Mid (S\$4000 – 5999)	91 (26.1%)	16 (21.9%)	26 (26.0%)	20 (19.4%)	29 (39.7%)	
Low (< S\$4000)	185 (53.0%)	36 (49.3%)	52 (52.0%)	64 (62.1%)	33 (45.2%)	
Maternal age at delivery (yr)	31.1 (5.3)	31.5 (4.8)	30.5 (5.4)	30.4 (5.4)	32.4 (5.4)	0.03
Pre-pregnancy BMI (kg/m <sup>2</sup> )	22.64 (4.29)	22.23 (4.05)	21.60 (3.59)	24.01 (4.71)	22.75 (4.44)	<0.001
Gestational fasting plasma glucose (mmol/L)	4.39 (0.47)	4.36 (0.34)	4.32 (0.40)	4.45 (0.57)	4.44 (0.51)	0.15
Gestational 2-hour plasma glucose (mmol/L)	6.36 (1.36)	6.14 (1.44)	6.29 (1.23)	6.38 (1.30)	6.67 (1.52)	0.10
Gestational diabetes						0.02
No	310 (85.6%)	68 (88.3%)	93 (87.7%)	94 (89.5%)	55 (74.3%)	
Yes	52 (14.4%)	9 (11.7%)	13 (12.3%)	11 (10.5%)	19 (25.7%)	
<b>Child characteristics</b>						
Sex						0.80
Girl	188 (49.9%)	37 (46.8%)	57 (52.3%)	57 (51.8%)	37 (46.8%)	
Boy	189 (50.1%)	42 (53.2%)	52 (47.7%)	53 (48.2%)	42 (53.2%)	
Prematurity						0.03
Term	351 (93.1%)	76 (96.2%)	95 (87.2%)	104 (94.5%)	76 (96.2%)	
Preterm	26 (6.9%)	3 (3.8%)	14 (12.8%)	6 (5.5%)	3 (3.8%)	
Birthweight (kg)	3.08 (0.43)	3.13 (0.35)	2.94 (0.50)	3.18 (0.44)	3.10 (0.35)	<0.001
Size at birth						0.02
Appropriate-for-gestational-age	269 (71.4%)	59 (74.7%)	70 (64.2%)	79 (71.8%)	61 (77.2%)	
Small-for-gestational-age	44 (11.7%)	7 (8.9%)	23 (21.1%)	7 (6.4%)	7 (8.9%)	
Large-for-gestational-age	64 (17.0%)	13 (16.5%)	16 (14.7%)	24 (21.8%)	11 (13.9%)	
<b>Adiposity markers at 6 years</b>						
z-BMI	-0.01 (1.32)	-0.35 (0.56)	-1.12 (0.76)	1.15 (1.27)	0.27 (1.12)	<0.001



Body composition and child cardiometabolic profile

z-height	-0.09 (1.01)	-0.27 (0.93)	-0.38 (0.96)	0.16 (0.97)	0.14 (1.06)	<0.001
Fat mass (kg)	4.38 (2.52)	2.99 (0.52)	2.87 (0.70)	6.24 (3.33)	5.25 (1.88)	<0.001
FMI (kg/m <sup>2</sup> )	3.23 (1.64)	2.28 (0.40)	2.21 (0.49)	4.49 (2.08)	3.82 (1.20)	<0.001
Lean mass (kg)	12.46 (1.89)	13.08 (1.30)	10.99 (1.35)	13.85 (1.72)	11.93 (1.55)	<0.001
LMI (kg/m <sup>2</sup> )	9.33 (1.00)	9.95 (0.53)	8.47 (0.75)	10.15 (0.69)	8.76 (0.62)	<0.001
<b>Metabolic markers at 6 years</b>						
Fasting plasma glucose (mmol/L)	4.53 (0.38)	4.53 (0.44)	4.51 (0.40)	4.50 (0.36)	4.59 (0.32)	0.50
Fasting insulin (pmol/L)	30.62 (16.25)	27.43 (13.54)	26.58 (14.11)	33.56 (15.77)	35.00 (19.83)	0.01
Homeostasis model assessment of insulin resistance (units)	0.90 (0.50)	0.81 (0.44)	0.77 (0.43)	0.98 (0.48)	1.04 (0.61)	0.01
Metabolic syndrome risk score	-0.08 (2.22)	-0.95 (1.47)	-0.97 (1.74)	0.67 (2.17)	0.90 (2.66)	<0.001
Fatty liver index	1.07 (1.43)	0.53 (0.18)	0.49 (0.20)	1.72 (2.00)	1.39 (1.57)	<0.001
<b>Cardiovascular markers at 6 years</b>						
Systolic blood pressure (mmHg)	101.06 (8.18)	100.55 (8.16)	99.30 (7.93)	102.84 (8.03)	101.50 (8.35)	0.01
Diastolic blood pressure (mmHg)	59.62 (5.48)	58.71 (5.07)	59.17 (5.48)	60.08 (5.58)	60.50 (5.61)	0.13

Abbreviations: FMI – fat mass index; LMI – lean mass index

Body composition and child cardiometabolic profile

Table 2: Associations of body composition groups with adiposity and cardiometabolic markers in 6-year-old children

	Low FMI-High LMI		Low FMI-Low LMI			High FMI-High LMI			High FMI-Low LMI		
	N	β (95% CI)	N	β (95% CI)	P	N	β (95% CI)	P	N	β (95% CI)	P
<b>Adiposity markers</b>											
z-BMI	66	Ref.	92	-0.72 (-1.05, -0.40)	<0.001	85	1.43 (1.11, 1.76)	<0.001	62	0.61 (0.25, 0.96)	<0.001
z-height	66	Ref.	92	-0.16 (-0.47, 0.14)	0.29	85	0.27 (-0.04, 0.58)	0.08	62	0.15 (-0.19, 0.48)	0.39
<b>Metabolic markers</b>											
Fasting plasma glucose (mmol/L)	46	Ref.	67	-0.04 (-0.19, 0.11)	0.59	61	-0.06 (-0.21, 0.08)	0.39	50	0.02 (-0.13, 0.18)	0.76
Fasting insulin (pmol/L)	40	Ref.	56	-2.23 (-8.77, 4.31)	0.50	51	6.23 (-0.39, 12.85)	0.07	40	5.24 (-1.88, 12.36)	0.15
Homeostasis model assessment of insulin resistance (units)	40	Ref.	56	-0.08 (-0.28, 0.13)	0.47	51	0.18 (-0.03, 0.38)	0.10	40	0.15 (-0.07, 0.38)	0.18
Metabolic syndrome risk score	38	Ref.	55	-0.09 (-0.94, 0.77)	0.84	50	1.64 (0.77, 2.50)	<0.001	39	1.28 (0.34, 2.21)	0.008
Fatty liver index	31	Ref.	47	-0.05 (-0.66, 0.56)	0.86	43	1.15 (0.54, 1.77)	<0.001	37	0.51 (-0.14, 1.16)	0.12
<b>Cardiovascular markers</b>											
Systolic blood pressure (mmHg)	65	Ref.	90	-0.45 (-3.01, 2.10)	0.73	84	0.89 (-1.70, 3.48)	0.50	61	-0.93 (-3.75, 1.90)	0.52
Diastolic blood pressure (mmHg)	65	Ref.	90	0.67 (-1.11, 2.45)	0.46	84	0.94 (-0.86, 2.74)	0.31	61	1.79 (-0.17, 3.76)	0.07

Abbreviations: FMI – fat mass index; LMI – lean mass index

Models were adjusted for ethnicity, sex, household income, maternal age, pre-pregnancy body mass index, gestational diabetes, prematurity, and size at birth. Coefficients (β) shown are adjusted differences in adiposity and cardiometabolic markers between each body composition group and the Low FMI-High LMI reference group.

## Body composition and child cardiometabolic profile

Table 3. Differences in adiposity and cardiometabolic markers between the high fat mass index body composition groups in 6-year-old children

	High FMI-High LMI (vs. High FMI-Low LMI)	
	$\beta$ (95% CI)	P
<b>Adiposity markers</b>		
z-BMI	0.89 (0.45,1.32)	<0.001
z-height	0.15 (-0.50, 0.21)	0.42
<b>Metabolic markers</b>		
Fasting plasma glucose (mmol/L)	-0.12 (-0.26, 0.02)	0.09
Fasting insulin (pmol/L)	0.05 (-1.19,1.30)	0.93
Homeostasis model assessment of insulin resistance (units)	0.00 (-0.27,0.26)	0.98
Metabolic syndrome risk score	0.20 (-0.91,1.31)	0.72
Fatty liver index	0.69 (-0.23,1.61)	0.14
<b>Cardiovascular markers</b>		
Systolic blood pressure (mmHg)	1.47 (-1.38,4.31)	0.31
Diastolic blood pressure (mmHg)	-0.98 (-2.94,0.98)	0.33

Abbreviations: FMI – fat mass index; LMI – lean mass index

Models were adjusted for ethnicity, sex, household income, maternal age, pre-pregnancy body mass index, gestational diabetes, prematurity, and size at birth.

Body composition and child cardiometabolic profile

Table 4. Differences in cardiometabolic markers between the high fat mass index body composition groups, stratified by sex

	Fasting plasma glucose (mmol/L)		Diastolic blood pressure (mmHg)	
	$\beta$ (95%CI)	P	$\beta$ (95%CI)	P
<b>Girls</b>				
High FMI-Low LMI	Ref.		Ref.	
High FMI-High LMI	-0.29 (-0.55, -0.04)	0.03	-3.22 (-6.03, -0.41)	0.03
<b>Boys</b>				
High FMI-Low LMI	Ref.		Ref.	
High FMI-High LMI	0.06 (-0.12, 0.24)	0.49	1.65 (-1.59, 4.88)	0.31
P for interaction <sup>1</sup>	0.006		0.03	

Abbreviations: FMI – fat mass index; LMI – lean mass index

Models were adjusted for ethnicity, household income, maternal age, pre-pregnancy body mass index, gestational diabetes, prematurity, and size at birth.

<sup>1</sup> P-value of interaction term between two high fat mass index body composition groups and sex